Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 839 results for "merck co"

Grass Pollen Allergy? New Grastek Pill From Merck Hits Shelves Soon
InvestorPlace.com

Merck & Co Inc announces FDA approves RAGWITEK Sublingual tabl...

Thu, Apr 17 2014 Merck & Co Inc:U.S. Food and Drug Administration (FDA) has approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (12 Amb a 1-U).RAGWITEK is allergen extract indicated as immunotherapy for treatment of ... Reuters UK, 3 days ago
FDA approves Merck Cos Ragwitek Big News Network, 3 days ago
[x]  

183 images for merck co

Pharma Times, 3 days ago
Pharma Times, 2 weeks ago
4 Traders, 1 week ago
FOXNews.com, 3 days ago
Jutia Group, 2 weeks ago
Jutia Group, 3 weeks ago
92.9 WLMI, 6 days ago
Trade Arabia, 1 week ago
Pharma Letter, 1 week ago
Pharma Letter, 1 week ago

Merck (MRK) Trading Near $57.40 Resistance Level

After closing Wednesday at $56.26, Merck & Co Inc. (http://www.marketintelligencecenter.com/symbol/MRK"MRK) presents an attractive opportunity to get a 2.69% return in just 65 days, which is an annualized return of 15.10% (for comparison purposes ...
 Individual.com3 days ago Merck (MRK) Trading Near $57.23 Resistance Level  Individual.com6 days ago Merck (MRK) Showing Bullish Technicals With Resistance At $56.59  Individual.com1 week ago Merck (MRK) Trading Near $55.68 Support Level  Individual.com1 week ago

Merck (MRK) Showing Resistance Near $57.02

Merck & Co Inc. (http://www.marketintelligencecenter.com/symbol/MRK"MRK) presents a trading opportunity that offers a 2.88% return in just 66 days. A covered call on Merck at the $55.00 level expiring on Jun. '14 offers an assigned return rate of ...
 Individual.com4 days ago Merck (MRK) Showing Neutral Technicals With Resistance At $57.53  Individual.com6 days ago

Will Merck & Co. Inc Unseat Biotech's Hottest Drug?

No drug has hit the market running like Gilead Sciences ' ( NASDAQ: GILD ) freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory ...
 Motley Fool4 days ago Xencor Receives Milestone Payment From Merck & Co., Inc. For Initiation Of Phase 1 Clinical Trial Of A Biologic Candidate Using XmAb® Antibody Engineering Intellectual Property  BioSpace1 week ago Merck's Hepatitis C Pill Competes with Gilead  Telemanagement1 week ago Why Merck (MRK) Stock Is Higher This Morning  TheStreet.com1 week ago
[x]  
Motley Fool

2 Reasons Why Merck & Co. Is Crushing the Dow

The Dow Jones Industrials ( DJINDICES: ^DJI ) has finally lost some steam this year after its record-breaking gains in 2013. Specifically, the Dow Jones is presently down around 1% on the year. That said, some of its components are still marching ...
 Motley Fool4 days ago Why the Dow Jones Industrial Average Is Useless  Motley Fool2 days ago

Deadly Bacteria Draws New Interest With Drugmaker Bonus: Health

Drugmakers led by Merck & Co. and Sanofi (SAN) are searching for new weapons against a deadly bacteria implicated in hospital and nursing-home infections. Merck, Sanofi, Actelion Ltd. and Shire Plc (SHP) are among the companies vying to develop ...
 BusinessWeek1 week ago Deadly Bowel Infection Draws Drugmakers Seeking Cures  Bloomberg1 week ago New Direction For Drugmakers Such As Merck & Co., Inc., Sanofi (France): Seeking Cure For Deadly Bowel Infection  BioSpace1 week ago Merck joins race to copy Sanofi's diabetes drug Lantus  Reuters2 months ago
4 Traders

Research and Markets Adds Report: Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating

Research and Markets has announced the addition of the "Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating" report to its offerings. In a release, Research and Markets noted ...
 Individual.com1 week ago Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating  PredictWallStreet6 days ago Research and Markets: Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating  TMC Net6 days ago Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating  Individual.com1 week ago
[x]  
Bidness Etc

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

With the release of phase 2 data from Merck ( NYSE: MRK ) and phase 3 data from Bristol-Myers Squibb ( NYSE: BMY ) , the race for the new hepatitis C combination treatment is heating up. While leader Gilead Sciences ( NASDAQ: GILD ) ...
 Motley Fool6 days ago Merck's Hepatitis C Drug Makes Important Progress  Bidness Etc1 week ago Hepatitis C Virus Battle: Gilead Sciences (Nasdaq:GILD), Enanta Pharmaceuticals (Nasdaq:ENTA), Merck & Co (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), AbbVie (NYSE:ABBV)  Galaxy Stocks1 week ago Merck & Co., Inc. : BlackBerry CEO May Consider Exiting Handset Business; Celgene Corporation Favored over Natco in Pre-trial  4 Traders1 week ago
[x]  
Reuters

Reckitt Benckiser Said to Have Edge on Rivals for Merck Unit (1)

In the battle between global consumer-health companies for a multi billion dollar foot-care, allergy and sun-tan lotion business, Reckitt Benckiser Group Plc (RB/) has advantages that rivals will be hard pressed to match. The maker of Durex ...
 BusinessWeek1 week ago Reckitt Benckiser Plc The Front Runner To Buy Merck & Co., Inc.'s Consumer Health Unit: Sources  BioSpace1 week ago Sources say Reckitt Benckiser favourite to buy Merck & Co.'s consumer health unit: report  FirstWord Pharma1 week ago Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources  Reuters2 months ago
[x]  

Merck announces encouraging interim results from Phase II hepatitis C study

Merck has announced interim results from the ongoing C-WORTHy study, a multi-arm Phase II clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A ...
 Individual.com5 days ago Promising results for Merck & Co's hepatitis C drug combo  Pharma Letter1 week ago Merck & Co. reports promising mid-stage data for once-daily, all-oral hepatitis C regimen  FirstWord Pharma1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less